Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SR-B1 CRISPR Activation Plasmid (h): sc-400990-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SR-B1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- SR-B1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by SR-B1 CRISPR Activation Plasmid (h) and SR-B1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the SCARB1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SR-B1 Antibody (F-12): sc-518140
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SR-B1 CRISPR Activation Plasmid (h) | sc-400990-ACT | 20 µg | $397.00 | |||
SR-B1 CRISPR Activation Plasmid (h2) | sc-400990-ACT-2 | 20 µg | $397.00 |
SCARB1 encodes scavenger receptor class B type 1 (SR-B1), a multiligand cell-surface receptor that mediates selective uptake of cholesteryl esters from HDL and coordinates bidirectional lipid transport. SR-B1 helps regulate cellular cholesterol homeostasis and membrane composition, influencing steroidogenic output, lipid droplet dynamics, and lipoprotein metabolism in hepatocytes and steroidogenic tissues. Through these functions, SR-B1 interfaces with pathways controlling lipid handling and inflammatory signaling, including modulation of oxidative stress responses and innate immune receptor activity. Altered SCARB1/SR-B1 activity has been associated with dyslipidemia and atherosclerosis-related phenotypes and is frequently investigated for roles in metabolic remodeling and disease-relevant lipid signaling in human cells.
SR-B1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SCARB1 expression without altering the underlying DNA sequence.
SR-B1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SCARB1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SCARB1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous SR-B1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SCARB1 locus and enabling the study of SR-B1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of SR-B1 pathway restoration in tumor cells with silenced or reduced SCARB1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.